PD-1/PD-L1抑制剂治疗卵巢癌的研究进展

Research Progress of PD-1/PD-L1 Inhibitors in the Treatment of Ovarian Cancer

卵巢癌(Ovarian cancer, OC)的发病率居于女性生殖系统恶性肿瘤第三,仅次于宫颈癌和子宫内膜癌,其起病隐匿且缺乏有效的早期诊断指标,卵巢癌的预后是妇科恶性肿瘤中最差的,由于确诊时多数患者已属晚期,故化疗等综合治疗方案在卵巢癌中具有不可或缺的地位。近年来,基于对卵巢癌免疫微环境的广泛研究,提出将程序性死亡受体-1 (Programmed death 1, PD-1)/程序性死亡受体配体-1 (Programmed death ligand 1, PD-L1)抑制剂作为对卵巢癌的治疗方案。本文将对目前将PD-1/PD-L1抑制剂应用于卵巢癌的临床试验进行综述,以期为卵巢癌的综合治疗方案提供思路。

Ovarian cancer (OC) ranks third in the incidence of malignant tumours of the female reproductive system, after cervical cancer and endometrial cancer, with an insidious onset and a lack of effective early diagnostic indicators, and the prognosis of OC is the poorest among gynaecological malignant tumours. Since most patients are in the advanced stage at the time of diagnosis, chemotherapy and other comprehensive therapeutic regimens have an indispensable role in OC. In recent years, based on extensive research on the immune microenvironment of ovarian cancer, programmed death receptor-1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors have been proposed as a therapeutic option for ovarian cancer. In this paper, we will review the current clinical trials of PD-1/PD-L1 inhibitors applied to ovarian cancer, in order to provide ideas for comprehensive treatment options for ovarian cancer.